Results 91 to 100 of about 1,341 (183)

In Vitro Activitiy of Rezafungin in Comparison with Anidulafungin and Caspofungin against Invasive Fungal Isolates (2017 to 2022) in China

Journal of Fungi
The efficacy of different echinocandins is assessed by evaluating the in vitro activity of a novel antifungal, rezafungin, against invasive fungal isolates in comparison with anidulafungin and caspofungin.
Simin Yang, Feifei Wan, Min Zhang, Huiping Lin, Liang Hu, Ziyi Zhou, Dongjiang Wang, Aiping Zhou, Lijun Ni, Jian Guo, Wenjuan Wu   +10 more
doaj   +1 more source

Multicentre determination of rezafungin (CD101) susceptibility of Candida species by the EUCAST method [PDF]

Clinical Microbiology and Infection, 2018
Rezafungin (CD101) is a new long-acting echinocandin allowing weekly dosing, currently undergoing phase-II clinical trials for invasive candidiasis. The aim of this study was to assess rezafungin's in vitro activity against the most frequent Candida species following the EUCAST methodology.The susceptibility of 2018 clinical Candida isolates was ...
Arendrup, M. C., Meletiadis, J., Zaragoza, O., Jørgensen, K. M., Marcos-Zambrano, L. J., Kanioura, L., Cuenca-Estrella, M., Mouton, J. W., Guinea, J.   +8 more
openaire   +4 more sources

Aspiring Antifungals: Review of Current Antifungal Pipeline Developments

Journal of Fungi, 2020
Invasive fungal infections are associated with significant morbidity and mortality, and their management is restricted to a variety of agents from five established classes of antifungal medication.
Thomas J. Gintjee, Monica A. Donnelley, George R. Thompson   +2 more
doaj   +1 more source

Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis

Antimicrobial Agents and Chemotherapy
Rezafungin is a long-acting, intravenously administered echinocandin for the treatment of candidemia and invasive candidiasis (IC). Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and/or IC was demonstrated in the
J. B. Locke, C. Pillar, M. Castanheira, C. Carvalhaes, David R. Andes, J. Aram, Christina Andrzejewski, Ken Bartizal, Anita F Das, T. Sandison, George R Thompson, Peter G. Pappas   +11 more
semanticscholar   +1 more source

Multicomponent Synthesis of Fluorine‐Containing Bioactive Compounds and Drugs

European Journal of Organic Chemistry, Volume 28, Issue 38, October 15, 2025.
Multicomponent reactions are robust synthetic tools to assamble complex polyheterocycles and other interesting molecular architectures with potential application in medicinal chemistry, including their fluorine‐containing analogues. Fluorine atoms placed strategically into bioactive molecules often enhance essential pharmacokinetic parameters like ...
Ivette Morales‐Salazar, Perla Islas‐Jácome, Leonardo D. Herrera‐Zuñiga, Samuel Couve‐Bonnaire, Philippe Jubault, Eduardo González‐Zamora, Jean‐Philippe Bouillon, Alejandro Islas‐Jácome   +7 more
wiley   +1 more source

Repositioning Antimicrobial Peptides Against WHO‐Priority Fungi

Advanced Science, Volume 12, Issue 37, October 6, 2025.
The growing burden of drug‐resistant fungal infections, driven by pathogens such as Candida auris, Cryptococcus neoformans, and Aspergillus fumigatus, underscores the urgent need for novel antifungal therapies. This review explores antimicrobial peptides as promising agents with membrane‐disruptive activity, immunomodulatory properties, and delivery ...
Cesar Augusto Roque‐Borda, Kaila Petronila Medina‐Alarcón, João Paulo Soler Gonçalves Pereira, Thais Cristina dos Anjos Sevilhano, Brigitte Aguilar‐Morón, Fernando Díaz‐Cárdenas, Lucas Silva da Cruz, Francisco Humberto Xavier‐Júnior, Eduardo Festozo Vicente, João Perdigão, Beatriz G. de la Torre, Fernando Albericio, Fernando Rogério Pavan   +12 more
wiley   +1 more source

Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans [PDF]

, 2018
Background. While echinocandins demonstrate excellent efficacy against Candida species in disseminated infections and demonstrate potent minimal inhibitory concentration (MIC) values under standard susceptibility testing conditions, investigation under ...
Amanda L. Almaguer, Jeffrey B. Locke, Joanna L. Donatelli, Ken F. Bartizal   +3 more
core   +2 more sources

In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae [PDF]

Journal of Antimicrobial Chemotherapy, 2019
AbstractBackgroundRezafungin is a novel echinocandin with excellent activity against common Candida species; however, limited data are available regarding rare Candida species.MethodsWe determined the in vitro susceptibility of 689 clinical isolates of 5 common and 19 rare Candida species, as well as Saccharomyces cerevisiae. The activity of rezafungin
Tóth, Zoltán, Forgács, Lajos, Locke, Jeffrey B, Kardos, Gábor, Nagy, Fruzsina, Kovács, Renátó, Szekely, Adrien, Borman, Andrew M, Majoros, László   +8 more
openaire   +2 more sources

In Vitro Activity of Rezafungin Against Planktonic and Biofilm Forms of Candida albicans and Nakaseomyces glabratus Clinical Isolates from Vascular Infections in Poland: A Pilot Study

Pharmaceutics
Background/Objectives: Certain yeast species are recognized as significant opportunistic pathogens, capable of causing severe systemic infections, particularly in immunocompromised individuals or those with disrupted physiological barriers.
Iwona Skiba-Kurek, Magdalena Namysł, Katarzyna Kania, Joanna Czekajewska, Anna Sepioło, Tomasz Gosiewski, Aldona Olechowska-Jarząb   +6 more
doaj   +1 more source

Synthesis and Biological Evaluation of Novel 2‐(Piperidin‐4‐yl)‐1,2,3,4‐tetrahydroisoquinoline and 2‐(Piperidin‐4‐yl)decahydroisoquinoline Antimycotics

Archiv der Pharmazie, Volume 358, Issue 10, October 2025.
A series of 13 hybrid molecules of both lead structures were prepared using reductive amination as key reaction step. The antimycotic potency of the resulting compounds was evaluated against yeast and mold species. Two compounds showed remarkable potency against several yeasts, and even against Candida krusei.
Marie‐Christin Hain, Monika Klimt, Franz Bracher, Ulrike Binder, Jürgen Krauß   +4 more
wiley   +1 more source